Related Experiment Video
Updated: Mar 16, 2026
12:19
Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis
Published on: April 22, 2022
4.4K
5-Arylaminouracil Derivatives as Potential Dual-Action Agents
E S Matyugina1, M S Novikov2, D A Babkov2
1Engelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Acta Naturae
|October 21, 2015
Summary
Several 5-aminouracil derivatives inhibit both Mycobacterium tuberculosis and HIV-1 reverse transcriptase. These compounds show efficacy without causing toxicity in vitro and ex vivo, offering potential therapeutic applications.
Area of Science:
- Medicinal Chemistry
- Virology
- Microbiology
Background:
- 5-aminouracil derivatives are known to inhibit Mycobacterium tuberculosis growth.
- Human Immunodeficiency Virus type 1 (HIV-1) reverse transcriptase is a key target for antiviral therapies.
Purpose of the Study:
- To investigate the potential of 5-aminouracil derivatives as inhibitors of HIV-1 reverse transcriptase.
- To assess the in vitro and ex vivo toxicity of these compounds.
Main Methods:
- Testing 5-aminouracil derivatives for their inhibitory activity against HIV-1 reverse transcriptase.
- Evaluating compound toxicity in MT-4 cells (in vitro) and human tonsillar tissue (ex vivo).
Main Results:
- 5-aminouracil derivatives function as noncompetitive, non-nucleoside inhibitors of HIV-1 reverse transcriptase.
- These derivatives exhibit no observable toxicity in both in vitro and ex vivo models.
Conclusions:
- 5-aminouracil derivatives represent a promising class of compounds with dual activity against Mycobacterium tuberculosis and HIV-1.
- The lack of toxicity suggests their potential for further development as therapeutic agents.
Keywords:
5-(phenylamino)uracil derivatives5’-norcarbocyclic nucleoside analogsHIV and Mycobacterium tuberculosis co-infectiondual actionMore Related Videos
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
56
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
56
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
01:29Drugs for Treatment of Ulcerative Colitis in IBD
592
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
592
01:27Combined Effects of Drugs: Synergism
7.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.2K
01:26Targets for Drug Action: Overview
11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
01:11Aryldiazonium Salts to Azo Dyes: Diazo Coupling
3.8K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para...
3.8K